AABB is honored to welcome Tom Whitehead, co-founder of the Emily Whitehead Foundation and a tireless advocate for pediatric cancer immunotherapy, as the keynote speaker for the 2025 Annual Meeting Opening General Session.
In a story that has inspired millions, Tom Whitehead’s daughter, Emily, became the first pediatric patient in the world to receive chimeric antigen receptor (CAR) T-cell therapy after standard leukemia treatments failed. Her remarkable recovery — now cancer-free for more than 12 years — helped catalyze a new era in cellular therapies. Today, the Emily Whitehead Foundation continues to advance awareness, access, and research in immunotherapy, having supported more than 40,000 patients and raised over $2 million for scientific advancement.
In his keynote address, Mr. Whitehead will share the powerful journey behind Emily’s treatment and recovery, offering a deeply personal perspective on the impact of innovation, perseverance, and hope in the face of life-threatening illness. His story highlights not only the transformational potential of cell and gene therapies, but also the vital role of the healthcare community in delivering them.
The General Session will also include: - Opening remarks by AABB President Meghan Delaney, DO, MPH - AABB CEO Debra BenAvram’s welcome and organizational update - Presentation of the 2025 AABB President’s Awards, recognizing outstanding contributions to the field
This inspiring session marks the official launch of the 2025 AABB Annual Meeting and will lead directly into the Opening Reception in the Exhibit Hall — a lively opportunity to connect with colleagues, explore innovations, and celebrate the start of an exciting program in beautiful San Diego.
